TRexBio Q3 net loss widens 68% to $13.24 million
TRXB•TRexBio’s third-quarter 2026 net loss widened 68% year over year to $13.24 million, while research and development expenses rose 64% to $11.43 million.
1. Quarterly results
TRexBio reported a third-quarter 2026 net loss of $13.24 million, up 68% year over year. Research and development expenses increased 64% to $11.43 million, primarily due to higher clinical, preclinical, manufacturing, personnel and facility costs.
2. Cash and trials
The company’s October IPO raised $119 million in net proceeds, extending its expected cash runway into the second half of 2029. TRB-061 delivered positive Phase 1a results, with topline Phase 1b data in atopic dermatitis expected in mid-2027; a Phase 1 trial of TRB-071 is expected to begin in the first half of 2027, subject to regulatory clearance.
